ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 9

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

, , , ,

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.